Helicobacter pylori CAs inhibition.
Antibacterial
Cancer
Carbonic anhydrase
Drug-resistance
Helicobacter pylori
Infections
Medicinal chemistry
Journal
The Enzymes
ISSN: 0423-2607
Titre abrégé: Enzymes
Pays: United States
ID NLM: 101637215
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
ppublish
Résumé
Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC: 4.2.1.1) from Hp, namely HpαCA and HpβCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.
Identifiants
pubmed: 39222992
pii: S1874-6047(24)00013-1
doi: 10.1016/bs.enz.2024.05.013
pii:
doi:
Substances chimiques
Carbonic Anhydrase Inhibitors
0
Anti-Bacterial Agents
0
Carbonic Anhydrases
EC 4.2.1.1
Isoenzymes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-241Informations de copyright
Copyright © 2024. Published by Elsevier Inc.